Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Stroke

Measuring disease-free life after thrombolysis

Nature Reviews Neurology volume 6, pages 361–362 (2010)Cite this article

Subjects

Analysis of two recombinant tissue plasminogen activator (rtPA) trials by means of the disability-adjusted life year metric has provided readily understandable data on the benefits of rtPA therapy in acute ischemic stroke. Approximately one-third of patients treated with rtPA could gain more than 4 years of healthy life, which is twice that previously estimated.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hong, K. S. & Saver, J. L. Years of disability-adjusted life gained as a result of thrombolytic therapy for acute ischemic stroke. Stroke 41, 471–477 (2010).

    Article  Google Scholar 

  2. [No authors listed] Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333, 1581–1587 (1995).

  3. Dachs, R. J., Burton, J. H. & Joslin, J. A user's guide to the NINDS rt-PA stroke trial database. PLoS Med. 5, e113 (2008).

    Article  Google Scholar 

  4. Slot, K. B. et al. Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ 336, 376–379 (2008).

    Article  Google Scholar 

  5. Eriksson, M., Norrving, B., Terent, A. & Stegmayr, B. Functional outcome 3 months after stroke predicts long term survival. Cerebrovasc. Dis. 25, 423–429 (2008).

    Article  Google Scholar 

  6. Fagan, S. C. et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 50, 883–890 (1998).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

S. C. Fagan is financially supported by research grants from the National Institute of Neurological Disorders and Stroke, VA Merit Review and the American Legion.

Author information

Authors and Affiliations

  1. Program in Clinical and Experimental Therapeutics, University of Georgia College of Pharmacy, HM 1200 Medical College of Georgia, Augusta, 30912, GA, USA

    Susan C. Fagan

Authors
  1. Susan C. Fagan
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Susan C. Fagan has received honoraria from Ferrer and Pfizer for consulting. She has also received research funding from Pfizer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fagan, S. Measuring disease-free life after thrombolysis. Nat Rev Neurol 6, 361–362 (2010). https://doi.org/10.1038/nrneurol.2010.79

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2010.79

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing